Healthcare Pharmaceuticals Ltd. (HPL) and Eli Lilly and Company announced the launch of Trulicity® (dulaglutide) in Bangladesh on Friday, 7th August 2020 at Hotel Intercontinental, Dhaka. Trulicity® is the first once-weekly, injectable medication designed to improve blood sugar control in adults with Type 2 diabetes. Trulicity® is a class of drugs known as a glucagon - like peptide (GLP-1) receptor agonists. It is not insulin and mimics the effects of human GLP-1, a natural hormone that helps keep blood sugar levels normal, by releasing bodies own insulin after food intake. Studies done on Trulicity® have established its cardiovascular safety and weight reduction potential. Trulicity® will be administered by an easy to use, fixed-dose device that does not require mixing or measuring and can be given at any time of the day, independent of meals. It is available in 0.75 mg and 1.5 mg doses. "Trulicity will be marketed and distributed in Bangladesh by Healthcare Pharmaceuticals Ltd. All the leading Endocrinologists of the country were present in this event either in the venue or over Microsoft team online. Prof. A K Azad Khan, President, Diabetes Association of Bangladesh, Md Sayefuddin, Secretory General, Diabetic Association of Bangladesh, Prof. Faruque Pathan, President, Bangladesh Endocrine Society, were present as chief guest, special guest and key note speaker respectively. Type 2 diabetes is a progressive disease and in Bangladesh many patients do not meet their treatment goals. Trulicity is a new, non-insulin, injectable (once in a week) that has been designed keeping patients' needs and convenience in mind," said Professor AK Azad Khan, President, Diabetic Association of Bangladesh (BADAS). Mr. Luca Visini, Managing Director, Eli Lilly & Co. for India, Bangladesh. Nepal & Sri Lanka & Md. Halimuzzaman, DMD & CEO of Healthcare Pharmaceuticals Ltd were also present on this occasion. Trulicity will open up newer avenues in diabetes management and provide healthcare professionals with a better way to manage diabetes," said Md. Halimuzzaman, DMD & CEO, Healthcare Pharmaceuticals Ltd.
